Assertio to Be Acquired for $21.80 Cash Per Share; $152.2M in Equity and Debt Commitments Secured
summarizeSummary
Assertio Holdings has entered into an amended and restated merger agreement to be acquired by Garda Therapeutics for $21.80 per share in cash. This definitive offer follows earlier announcements of an amended merger agreement and an increased tender offer, now specifying the exact cash consideration. The transaction is supported by $22.2 million in equity commitments and $130 million in debt commitments, totaling $152.2 million, which provides clear financing for the deal. This acquisition at a premium offers certainty for shareholders and is a highly material event for the company. Investors will now watch for the commencement of the tender offer by May 4, 2026, and the closing by the outside date of July 2, 2026, subject to customary conditions.
At the time of this announcement, ASRT was trading at $21.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $119M. The 52-week trading range was $8.61 to $20.45. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.